SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

The SPDR Gold Shares ETF (GLD) is experiencing a sharp sell-off as a strengthening dollar and rising Treasury yields trigger a wave of liquidation among investors who previously viewed the asset as a safe haven. Community sentiment is deeply divided, with many traders frustrated by the lack of defensive performance during geopolitical instability, while others advocate for long-term accumulation as they believe current price levels represent a significant opportunity before potential future volatility.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is seeing intense volatility as investors weigh the fallout of a federal indictment involving a co-founder and employees accused of smuggling AI technology to China, while the company maintains it was a victim of deception. The community is deeply divided between bargain-hunting bulls who see a buying opportunity in the stock's massive sell-off and bearish traders who fear further regulatory crackdowns, potential delisting, and the erosion of corporate trust.

AleAnna, Inc. operates as a technology-driven energy company, which engages in supplying low-carbon natural gas and renewable natural gas to Italy. The company was founded in 2007 and is headquartered in Dallas, TX.

AleAnna Inc. - Ordinary Shares - Class A

AleAnna is surging as geopolitical instability in the Persian Gulf sparks critical supply chain concerns, with traders betting on the firm's role in European energy security following significant infrastructure disruptions. The community is intensely focused on the stock's potential for a multi-day rally, with many active traders debating the impact of the ongoing conflict on natural gas prices and debating whether to hold or lock in gains during this period of high volatility.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

The market is experiencing significant volatility and uncertainty as traders react to a high-stakes geopolitical standoff in the Middle East, specifically a deadline regarding the Strait of Hormuz. Community discussion is heavily divided between bears betting on a deeper downturn driven by energy supply fears and recessionary concerns, and bulls attempting to buy the dip in anticipation of a potential ceasefire or market recovery.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently facing significant selling pressure and community debate following news of the company's joint semiconductor venture with SpaceX, while investors simultaneously react to a legal verdict finding Elon Musk liable for misleading Twitter shareholders. The stock is seeing polarized discussion as market participants weigh these high-stakes infrastructure ambitions against ongoing concerns regarding delivery growth, the company's high valuation, and broader macroeconomic volatility.

Caledonia Mining Corp. Plc engages in the exploration, development, and production of gold and other precious metals from its mineral properties. Its projects include Blanket Gold Mine and Maligreen. The company was founded on February 5, 1992 and is headquartered in St. Helier, the United Kingdom.

Caledonia Mining Corporation Plc

Caledonia Mining is gaining investor attention as the community weighs strong production growth and high profit margins against the geopolitical risks associated with its Zimbabwe-based operations. Discussions are heavily focused on the potential of the Bilboes project to scale production, alongside recent corporate developments like BlackRock increasing its stake and the company's strategic decision to sell its solar assets to fund further expansion.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is experiencing heightened volatility as investors weigh President Trump's 48-hour ultimatum against Iran and the potential for a significant escalation in Middle East tensions. Community discussions are centered on the impact of surging oil prices, bond market fluctuations, and potential threats to global energy infrastructure, with traders debating whether these geopolitical risks are already priced into the index.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending as investors weigh the significant supply disruptions to global natural gas infrastructure against the company's aggressive expansion and capacity to leverage spot market pricing. The community remains highly focused on potential short squeeze setups and the long-term impact of regional geopolitical instability on LNG energy prices.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is currently experiencing heightened community debate as investors weigh the project's long-term technical potential against its recent price volatility and market underperformance. While some retail participants continue to accumulate shares based on long-term project milestones, others are actively exiting and voicing frustration over the lack of consistent momentum compared to the broader crypto market.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

The iShares 20+ Year Treasury Bond ETF (TLT) is experiencing significant downward pressure as investors pivot toward risk-off sentiment, driven by persistent inflation concerns and fears of a systemic credit shock tied to surging energy prices. Community discussion is heavily focused on the bond market signaling a long-term inflationary regime, with many traders debating whether current yields offer a compelling entry point for capital preservation versus the risk of further volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Enveric Biosciences Announces Registration of Five Trademarks

Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders...

<ul class="summary-bullets"><li>The patent in question is about new chemical versions of psilocybin to treat mental health conditions such as depression, anxiety, and post-traumatic stress disorder.</li><li>Enveric identified that Gilgamesh’s petition may target claims that could be relevant to another family of patents owned by the company.</li><li>These patents are aimed at the treatment of depression and anxiety, and Enveric noted that the company has licensed them to third parties for development.</li></ul>Enveric Biosciences Inc. (ENVB) on Wednesday announced that Gilgamesh Pharmaceuticals has withdrawn a challenge against the company’s patent.Enveric stated that following the withdrawal of Gilgamesh’s challenge, there are no remaining challenges against its patent.<a href="https://stocktwits.com/symbol/ENVB">Enveric shares</a> were up more than 4% in Wednesday’s opening trade.<h2 class="st-heading-2">What Is The Patent In Question About?</h2>The patent in question is about new chemical versions of psilocybin to treat mental health conditions such as depression, anxiety, and post-traumatic stress disorder (PTSD).Gilgamesh filed a challenge against the patent in August 2025. Subsequently, AbbVie Inv. (ABBV) acquired bretisilocin from the company in a deal valued at up to $1.2 billion. Gilgamesh notified the U.S. Patent and Trademark Office (USPTO) that it had become a wholly-owned subsidiary of an entity owned by AbbVie.AbbVie filed a request with the USPTO in October to withdraw the post-grant review (PGR) petition filed by Gilgamesh.Enveric identified that Gilgamesh’s petition may target claims that could be relevant to another family of patents owned by the company. These patents are aimed at the treatment of depression and anxiety, and Enveric noted that the company has licensed them to third parties for development.Under its license terms, the company is eligible to receive aggregate upfront, development, and sales milestones potentially totaling up to $205 million, in addition to royalties on future sales.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/ENVB">Enveric Biosciences</a> trended in the ‘bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.One bullish user on Stocktwits termed the withdrawal of the petition against Enveric as “huge news.”<stembedurl>https://stocktwits.com/Luckyjs38/message/645825647</stembedurl><a href="https://stocktwits.com/symbol/ENVB">ENVB stock</a> is down 39% year-to-date and 84% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/vnda-stock-rises-after-fda-accepts-imsidolimab-gpp-treatment/cZRyPfnRIGR">Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Enveric Biosciences Announces Withdrawal Of Petition Against Its Patent — ENVB Stock Rises

The company stated that, following the withdrawal of Gilgamesh’s challenge, there are no remaining challenges against its patent.

Equity

Enveric Biosciences Announces Withdrawal of Petition Against Its Patent

Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data

Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option

Enveric Biosciences, Inc. (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological...

Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Enveric Biosciences, Inc. (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological...

<ul class="summary-bullets"><li>Enveric stated that with the molecules covered by the patent, it may be able to target key receptors in new ways.</li><li>The company said this could enable the development of drug candidates with efficacy and safety profiles previously unattainable.</li><li>Enveric added that the expanded pipeline of molecules protected by patents allows it to license and partner with pharmaceutical firms that are investing in the treatment of neuropsychiatric conditions.</li></ul>Enveric Biosciences Inc. (SOPA) shares gained over 7% in Monday’s pre-market trade after the company announced that it has been issued a patent that covers novel molecules with likely applications for the treatment of neuropsychiatric conditions.The company said that U.S. Patent No. 12,492,179 extends the protection for its pipeline of potentially neuroplastogenic, non-hallucinogenic molecules.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/ENVB">Enveric Biosciences</a> trended in the ‘bearish’ territory at the time of writing.<h2 class="st-heading-2">Licensing Opportunity</h2>Enveric stated that with the molecules covered by the patent, it may be able to target key receptors in new ways. The company said this could enable the development of drug candidates with efficacy and safety profiles previously unattainable.Enveric added that the expanded pipeline of molecules protected by patents allows it to license and partner with pharmaceutical firms that are investing in the treatment of neuropsychiatric conditions.<h2 class="st-heading-2">Patent Details</h2>Enveric stated that the molecules covered by this patent are based on known compounds with relevant pharmacological activity. It added that these compounds are chemically altered to improve efficacy while reducing side effects compared to existing compounds.“Enveric’s growing pipeline of patented molecules expands the available opportunities to develop next-generation treatments for neuropsychiatric conditions, leveraging our innovative research,” said Enveric CEO Joseph Tucker.Enveric is a Massachusetts-based biotechnology company focused on developing small-molecule neuroplastogenic therapeutics for the treatment of psychiatric and neurological disorders.<a href="https://stocktwits.com/symbol/ENVB">ENVB stock</a> is down 99.6% year-to-date and 99.5% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/paul-krugman-warns-2026-worse-for-small-businesses/cL75twFRExT">Paul Krugman Warns 2026 Will Be Worse For Small Businesses, A Month After Small Firms Cut 120,000 Jobs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is ENVB Stock Rising Today?

The company said that U.S. Patent No. 12,492,179 extends the protection for its pipeline of potentially neuroplastogenic, non-hallucinogenic molecules.

Enveric Biosciences Announces Patent Issuance

Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds

<ul class="summary-bullets"><li>The USPTO’s Notice of Allowance signals that the agency has determined the patent is likely to be granted.</li><li>By securing this intellectual property, Enveric gains a competitive edge in the neuropsychiatric treatment space.</li><li>Enveric’s stock surged 106% in Wednesday’s premarket.</li></ul>Enveric Biosciences (ENVB) stock is drawing investors' attention on Wednesday after the company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application covering its EVM301 Series of molecules.<a href="https://stocktwits.com/symbol/ENVB/sentiment">Enveric’s stock</a> traded over 106% higher in Wednesday’s premarket.&nbsp;<h2 class="st-heading-2">Patent Focus and Potential</h2>The USPTO’s Notice of Allowance signals that the agency has determined the patent is likely to be granted, providing Enveric with intellectual property protection for its neuroplastogenic compounds.“We believe EB-003 holds great potential as the first known compound designed to selectively engage both 5-HT₂A and 5-HT₁B receptors to deliver fast-acting, durable antidepressant and anxiolytic effects, while being specifically designed to promote neuroplasticity and minimize hallucinogenic effects, allowing administration in outpatient setting,” said Joseph Tucker, CEO, Enveric.&nbsp;By securing this intellectual property, Enveric gains a competitive edge in the neuropsychiatric treatment space, particularly for patients with limited therapeutic options. The patent also enhances the company’s ability to pursue future research and commercialization of its EVM301 compounds.<h2 class="st-heading-2">What Are Stocktwits Users Saying?&nbsp;</h2>The stock was the second-most trending equity ticker on Stocktwits. Retail sentiment around the stock jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day. Message volume improved to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<figure class="image"><img style="aspect-ratio:936/103;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_10_090740_png_d70c080d0b.webp" alt="ENVB’s Sentiment Meter and Message Volume as of 09:00 a.m. ET on Dec. 10, 2025 | Source: Stocktwits" width="936" height="103"><figcaption>ENVB’s Sentiment Meter and Message Volume as of 09:00 a.m. ET on Dec. 10, 2025 | Source: Stocktwits</figcaption></figure>A bullish Stocktwits user said that if the drug proves safe and effective, a potential buyout exceeding $1 billion could be possible.&nbsp;<stembedurl>https://stocktwits.com/Luckyjs38/message/638708222</stembedurl>Another user expressed optimism about the low float and fresh IP update.&nbsp;<stembedurl>https://stocktwits.com/Caicong/message/638709397</stembedurl>ENVB stock has lost over 90% of its value year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-beat-stock-rocket-72-in-pre-market-today/cLIH2RhREV2">Why Did BEAT Stock Rocket 72% In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Various substances are placed on cooling blocks in the PCR laboratory of the State Office for Agriculture, Food Safety and Fisheries.

Why Did ENVB Stock More Than Double In Value Today?

The company received a Notice of Allowance from the United States Patent and Trademark Office for its patent application.

Enveric Biosciences, Inc. is a biotechnology company which engages in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company was founded on February 28, 1994 and is headquartered in Cambridge, MA.

ENVB
Enveric Biosciences Inc

Feed

News

Sentiment

Fundamentals

Info

Latest ENVB News

ENVBEnveric Biosciences Inc